Martin D. Madaus
Martin D. Madaus's purchase track record
How the stock did after each of Martin D. Madaus's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/8/2025 | RGEN | $202K | +28.2% | +27.6% | +8.5% |
| 11/19/2024 | AZTA | $201K | +8.5% | -30.9% | +0.4% |
| 6/14/2024 | RGEN | $202K | +11.4% | +24.5% | +11.4% |
| 5/4/2023 | RGEN | $238K | +7.5% | -13.2% | +6.3% |
| 8/10/2022 | QTRX | $756K | +10.4% | +66.0% | -2.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Quanterix Highlights Spatial Biology Innovation at ESSB 2026. Quanterix announced it met its spatial biology content innovation commitments during the ESSB 2026 event. The company showcased new tools and data sets that support advanced spatial analysis. This demonstrates progress in its product roadmap and may strengthen its position in the spatial biology market.
Transaction History
| AZTA | ▼ Sell | Tax Withholding | 1,456 | $50K | 9/22/2026 | View on chart |
| AZTA | ▲ Buy | Grant | 36,653 | $0 | 9/14/2026 | View on chart |
| HAE | ▲ Buy | Grant | 2,538 | — | 7/24/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 995 | $0 | 5/14/2026 | View on chart |
| RGEN | ▲ Buy | Open Market | 1,800 | $202K | 8/8/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 973 | $0 | 5/15/2025 | View on chart |
| QTRX | ▲ Buy | Grant | 7,435 | $0 | 1/2/2025 | View on chart |
| AZTA | ▲ Buy | Open Market | 4,940 | $201K | 11/19/2024 | View on chart |
| RGEN | ▲ Buy | Open Market | 915 | $114K | 6/14/2024 | View on chart |
| RGEN | ▲ Buy | Open Market | 700 | $88K | 6/14/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 701 | $0 | 5/16/2024 | View on chart |
| AZTA | ▲ Buy | Grant | 2,465 | $163K | 2/12/2024 | View on chart |
| QTRX | ▲ Buy | Grant | 2,947 | $0 | 1/2/2024 | View on chart |
| LAB | ▲ Buy | Grant | 1,574 | $4K | 10/20/2023 | View on chart |
| LAB | ▲ Buy | Grant | 26,376 | $0 | 6/14/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 686 | $0 | 5/18/2023 | View on chart |
| RGEN | ▲ Buy | Open Market | 500 | $78K | 5/8/2023 | View on chart |
| RGEN | ▲ Buy | Open Market | 500 | $80K | 5/5/2023 | View on chart |
| RGEN | ▲ Buy | Open Market | 500 | $81K | 5/4/2023 | View on chart |
| RGEN | ▼ Sell | Other | 11 | $2K | 3/24/2023 | View on chart |
| LAB | ▲ Buy | Grant | 29,665 | $0 | 2/20/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 111 | $0 | 2/6/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 8,083 | $0 | 1/3/2023 | View on chart |
| QTRX | ▲ Buy | Open Market | 89,667 | $756K | 8/10/2022 | View on chart |
| LAB | ▲ Buy | Grant | 30,914 | $0 | 6/15/2022 | View on chart |
| LAB | ▲ Buy | Grant | 15,852 | $0 | 4/4/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 427 | $18K | 1/3/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 2,668 | $0 | 1/3/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 354 | $18K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
AZTA Featured in Volatile Stock List
Azenta Inc. was included in a recent article discussing volatile stocks with promising prospects. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $37.00. This mention highlights the company's status as a high-beta asset in the current market environment.
AZTA Featured in Volatile Stock List. Azenta Inc. was included in a recent article discussing volatile stocks with promising prospects. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $37.00. This mention highlights the company's status as a high-beta asset in the current market environment.